AS/Spondyloarthritis

ICYMI: Issues in AxSpA: Treatment Intensification, Pregnancy

Save

Sheila Reyes, MD

Dec 01, 2023

A lot of interesting studies will be presented at the poster sessions on Sunday, November 12 and some of them address practical real-world issues such as treatment intensification and the impact of pregnancy on axSpA imaging.

Read Article

Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting up to 50% of patients in some age groups. https://t.co/uhlnpmLwoP https://t.co/NRW0PlD43a

Dr. John Cush @RheumNow( View Tweet )

Nov 27, 2023

Undiagnosed IBD in AxSpA Dr. Eric Dein (Summit, New Jersey) discusses Abstract #0495 presented at the ACR 2023 Convergence meeting in San Diego. https://t.co/QAC6fhSQ7Q https://t.co/BxNQwQ9nwc

Dr. John Cush @RheumNow( View Tweet )

Nov 26, 2023

Watch: Deep Neural Networks and Radiographic Progression in AxSpA Dr. Antoni Chan discusses abstracts 1389 and 1398 presented at the 2023 ACR Convergence in San Diego, CA. https://t.co/F9hpNvmvVc https://t.co/xR0uW1CkUw

Dr. John Cush @RheumNow( View Tweet )

Nov 24, 2023

Do We Stop or Continue Treatment?

Save

Kathryn H. Dao, M.D.

Nov 20, 2023

Remission had been a dream, an elusive concept. But then, with the introduction of biologics, conventional synthetic and targeted synthetic DMARDS, patients are able to live longer and with a better quality of life. While these therapeutics have been helpful, they are expensive and carry

Read Article

JAKi and TYK2i: What to use and when?

Save

Janet Pope, MD, MPH, FRCPC

Nov 20, 2023

You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose.

Read Article

IV Secukinumab for AxSpa The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. https://t.co/JhOvPIXOMN https://t.co/GoV62NjSmf

Dr. John Cush @RheumNow( View Tweet )

Nov 20, 2023

Watch: SpA Insights: New Therapies https://t.co/fkFYpEnDoX https://t.co/bcVJfl2un2

Dr. John Cush @RheumNow( View Tweet )

Nov 19, 2023

Can Rheumatologists Accurately Diagnose axSpA in Patients with Chronic Back Pain?

Save

Sheila Reyes, MD

Nov 17, 2023

Chronic low back pain is a common complaint that brings patients to the doctor’s attention. Although the majority of low back pain is mechanical in nature, an important minority is inflammatory in nature. Therefore, prompt referral to a rheumatologist is warranted particularly in the presence

Read Article

Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI

Dr. John Cush @RheumNow( View Tweet )

Nov 17, 2023

RHEUM Survey Question: Your choice of a biologic in patients with SpA is mostly influenced by? CLICK here to answer: https://t.co/afJmqzzPYi

Dr. John Cush @RheumNow( View Tweet )

Nov 15, 2023

Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY

Mithu Maheswaranathan, MD ( View Tweet )

Nov 14, 2023

Anterior uveitis incidence across different axSpA treatments Large review and meta-analysis on TNFi, IL-17i, JAKi Immunomodulatory therapy protective against uveitis flare Greatest in TNFi and JAKi @RheumNow #ACR23 Abs# 2550 https://t.co/l3BTL3GuRt

Robert B Chao, MD ( View Tweet )

Nov 14, 2023

Dr. @drpnash @RheumNow ➡️Difficult to treat Axial SpA ; 23,0000 🧍‍♀️🧍: 1-Failure of 3 biolo - targ synth, or different mechanism of action. 2- Around 10% of patients. 1-Female. 2-Peripheral arthritis. 3-Psoriasis 4-Lipid , HTN, Smoking. https://t.co/B99TcXjjiF… #ACR23

Nouf Al hemmadi ( View Tweet )

Nov 14, 2023

A#2545 IV SEC for SpA #ACR23 @Rheumow Approved by FDA, though diff dose Who: Medicare/cost/QoL benefit for IV or obese (wt based dose) W16: 41% ASAS40 v 23% PBO W16, PBO switched to SEC. Efficacy W52 (SEC 67%, PBO/Sec 75%) SAE 6%, discontinuation 3.5% #ACRBest https://t.co/ruW0ys49gk

Eric Dein ( View Tweet )

Nov 14, 2023

A#2546 Anti-IFX Ab in AS #ACR23 @RheumNow Anti-IFX in 45% in f/u, 85% in 1st yr MTX decr anti-IFX (18 v 42%) Anti-IFX - higher inflamm markers, infus rxn, lower serum levels and Rx fail Pt w/o anti-IFX Ab more likely to tolerate tapering https://t.co/eN9SqGyGgm

Eric Dein ( View Tweet )

Nov 14, 2023

A#2547 #ACR23 @RheumNow Diff 2 Treat (D2T) AxSpa D2T: fail 2+ b/tsDMARDs w 2 MoA Very D2T: failure of Rx in less than 2 yrs 28% D2T, 3.8% Very D2T (Compare to 7-10% D2TRA) More likely: peripheral, uveitis, higher BASDAI, FM Very D2T also w IBD, higher CRP, longer dis duration https://t.co/HcIXnDRrIq

Eric Dein ( View Tweet )

Nov 14, 2023

Another infusion option for axSpA! INVIGORATE-1: Phase 3 RCT of IV Secukinumab in axSpA Efficacious - ASAS40 response sustained thru 52 weeks Safety profile similar to subq version @RheumNow #ACR23 Abs#2545 https://t.co/biC8p3p6dl

Robert B Chao, MD ( View Tweet )

Nov 14, 2023

Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab

Save

Meral K. El Ramahi, MD, FACP, FACR

Nov 14, 2023

Acute anterior uveitis is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA) affecting up to 50% of patients in some age groups. AAU can have a significant impact on quality of life with risk of permanent visual deficits if not adequately treated.

Read Article

Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR

Janet Pope ( View Tweet )

Nov 14, 2023

Super interesting SpA phenotypical type world map. #ACR23 Abs #2195 continues to prove how heterogenous this disease is and the need for additional therapeutic agents for improved patient outcomes. https://t.co/hpKY7usUUb @rheumnow https://t.co/xJ1bx6wOC0

Dr. Rachel Tate ( View Tweet )

Nov 14, 2023

In this older grp of pts w/ chronic LBP, significant overlaps of deg & inflamm features on spinal imaging of DC, DISH & axSpA pts were seen Also, +comorbids: HTN in DC; DM in DISH; smoking in axSpA THM? DC & DISH are also axSpA mimics #ACR23 ABST1862 @Rheumnow @rheumarhyme https://t.co/uNIwRchF1g

sheila ( View Tweet )

Nov 14, 2023

Will postpartum BME ⏩axSpA-like structural lesions? Study by Varkas et al show there was no significant dev't of axSpA-like lesions on MRI in postpartum women 5 yrs after delivery. Postpartum BME likely sec to transient mech stress-induced SI BME #ACR23 ABST1892 @RheumNow https://t.co/KJ3DngmkbI

sheila ( View Tweet )

Nov 14, 2023

Always refreshing to hear from another specialist's point of view Cardiologist @Bweber04 on CVD and rheumatologic diseases Increased risk of death, MI and HF exacerbation in our pt population Increased all cause mortality @RheumNow #ACR23 https://t.co/yOkPOmxU4N

Robert B Chao, MD ( View Tweet )

Nov 14, 2023